C5 and COVID-19: Vlaar et al. noted that the administration of IFX-1 (vilobelimab), a monoclonal antibody against C5a, and Solris (eculizumab), a C5 blocking antibody, shows adequate efficacy in the management of moderate and severe COVID-19 cases [72].